Search Results - "Devisscher, Lindsey"

Osteopontin Expression Identifies a Subset of Recruited Macrophages Distinct from Kupffer Cells in the Fatty Liver by Remmerie, Anneleen, Martens, Liesbet, Thoné, Tinne, Castoldi, Angela, Seurinck, Ruth, Pavie, Benjamin, Roels, Joris, Vanneste, Bavo, De Prijck, Sofie, Vanhockerhout, Mathias, Binte Abdul Latib, Mushida, Devisscher, Lindsey, Hoorens, Anne, Bonnardel, Johnny, Vandamme, Niels, Kremer, Anna, Borghgraef, Peter, Van Vlierberghe, Hans, Lippens, Saskia, Pearce, Edward, Saeys, Yvan, Scott, Charlotte L.

“…Metabolic-associated fatty liver disease (MAFLD) represents a spectrum of disease states ranging from simple steatosis to non-alcoholic steatohepatitis (NASH)…”
Get full text

Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages by Lefere, Sander, Puengel, Tobias, Hundertmark, Jana, Penners, Christian, Frank, Anna Katharina, Guillot, Adrien, de Muynck, Kevin, Heymann, Felix, Adarbes, Vanessa, Defrêne, Evelyne, Estivalet, Céline, Geerts, Anja, Devisscher, Lindsey, Wettstein, Guillaume, Tacke, Frank

“…Peroxisome proliferator-activated receptors (PPARs) are essential regulators of whole-body metabolism, but also modulate inflammation in immune cells, notably…”
Get full text

Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges by Lefere, Sander, Devisscher, Lindsey, Tacke, Frank

Get more information

Rodent models of cholestatic liver disease: A practical guide for translational research by Gijbels, Eva, Pieters, Alanah, De Muynck, Kevin, Vinken, Mathieu, Devisscher, Lindsey

“…Cholestatic liver disease denotes any situation associated with impaired bile flow concomitant with a noxious bile acid accumulation in the liver and/or…”
Get full text

Unveiling the depletion of Kupffer cells in experimental hepatocarcinogenesis through liver macrophage subtype-specific markers by Lefere, Sander, Degroote, Helena, Van Vlierberghe, Hans, Devisscher, Lindsey

Get full text

Angiopoietin‐2 Promotes Pathological Angiogenesis and Is a Therapeutic Target in Murine Nonalcoholic Fatty Liver Disease by Lefere, Sander, Van de Velde, Frederique, Hoorens, Anne, Raevens, Sarah, Van Campenhout, Sanne, Vandierendonck, Astrid, Neyt, Sara, Vandeghinste, Bert, Vanhove, Christian, Debbaut, Charlotte, Verhelst, Xavier, Van Dorpe, Jo, Van Steenkiste, Christophe, Casteleyn, Christophe, Lapauw, Bruno, Van Vlierberghe, Hans, Geerts, Anja, Devisscher, Lindsey

“…Angiogenesis contributes to the development of nonalcoholic steatohepatitis (NASH) and promotes inflammation, fibrosis, and progression to hepatocellular…”
Get full text

Treatment of intestinal fibrosis in experimental inflammatory bowel disease by the pleiotropic actions of a local Rho kinase inhibitor by Holvoet, Tom, Devriese, Sarah, Castermans, Karolien, Boland, Sandro, Leysen, Dirk, Vandewynckel, Yves-Paul, Devisscher, Lindsey, Van den Bossche, Lien, Van Welden, Sophie, Dullaers, Melissa, Vandenbroucke, Roosmarijn E, De Rycke, Riet, Geboes, Karel, Bourin, Arnaud, Defert, Olivier, Hindryckx, Pieter, De Vos, Martine, Laukens, Debby

“…Abstract Background Intestinal fibrosis resulting in (sub)obstruction is a common complication of Crohn’s disease (CD). Rho kinases (ROCKs) play multiple roles…”
Get full text

Ursodeoxycholic Acid and Its Taurine- or Glycine-Conjugated Species Reduce Colitogenic Dysbiosis and Equally Suppress Experimental Colitis in Mice by Van den Bossche, Lien, Hindryckx, Pieter, Devisscher, Lindsey, Devriese, Sarah, Van Welden, Sophie, Holvoet, Tom, Vilchez-Vargas, Ramiro, Vital, Marius, Pieper, Dietmar H, Vanden Bussche, Julie, Vanhaecke, Lynn, Van de Wiele, Tom, De Vos, Martine, Laukens, Debby

“…The promising results seen in studies of secondary bile acids in experimental colitis suggest that they may represent an attractive and safe class of drugs for…”
Get full text

Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis by Puengel, Tobias, Lefere, Sander, Hundertmark, Jana, Kohlhepp, Marlene, Penners, Christian, Van de Velde, Frederique, Lapauw, Bruno, Hoorens, Anne, Devisscher, Lindsey, Geerts, Anja, Boehm, Stephanie, Zhao, Qihong, Krupinski, John, Charles, Edgar D., Zinker, Bradley, Tacke, Frank

“…(1) Background: With new potential drug targets emerging, combination therapies appear attractive to treat non-alcoholic steatohepatitis (NASH) and fibrosis…”
Get full text

Non-alcoholic steatohepatitis induces transient changes within the liver macrophage pool by Devisscher, Lindsey, Scott, Charlotte L., Lefere, Sander, Raevens, Sarah, Bogaerts, Eliene, Paridaens, Annelies, Verhelst, Xavier, Geerts, Anja, Guilliams, Martin, Van Vlierberghe, Hans

“…•A better understanding of the different liver macrophages during NASH is required.•We characterized the distinct macrophage subsets during MCD-induced NASH…”
Get full text

Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury by Gijbels, Eva, Vilas‐Boas, Vânia, Annaert, Pieter, Vanhaecke, Tamara, Devisscher, Lindsey, Vinken, Mathieu

“…Adverse outcome pathways (AOPs) have been recently introduced as tools to map the mechanisms underlying toxic events relevant for chemical risk assessment…”
Get full text

Hypoxia-regulated mechanisms in the pathogenesis of obesity and non-alcoholic fatty liver disease by Lefere, Sander, Van Steenkiste, Christophe, Verhelst, Xavier, Van Vlierberghe, Hans, Devisscher, Lindsey, Geerts, Anja

“…The pandemic rise in obesity has resulted in an increased incidence of metabolic complications. Non-alcoholic fatty liver disease is the hepatic manifestation…”
Get full text

Mechanisms and in vitro models of drug-induced cholestasis by Gijbels, Eva, Vilas-Boas, Vânia, Deferm, Neel, Devisscher, Lindsey, Jaeschke, Hartmut, Annaert, Pieter, Vinken, Mathieu

“…Cholestasis underlies one of the major manifestations of drug-induced liver injury. Drug-induced cholestatic liver toxicity is a complex process, as it can be…”
Get full text

The Gut-Liver Axis in Chronic Liver Disease: A Macrophage Perspective by De Muynck, Kevin, Vanderborght, Bart, Van Vlierberghe, Hans, Devisscher, Lindsey

“…Chronic liver disease (CLD) is a growing health concern which accounts for two million deaths per year. Obesity, alcohol overconsumption, and progressive…”
Get full text

NOX1 inhibition attenuates the development of a pro-tumorigenic environment in experimental hepatocellular carcinoma by Vandierendonck, Astrid, Degroote, Helena, Vanderborght, Bart, Verhelst, Xavier, Geerts, Anja, Devisscher, Lindsey, Van Vlierberghe, Hans

“…The poor prognosis of advanced HCC and limited efficacy of current systemic treatments emphasize the need for new or combined targeted therapies. The…”
Get full text

The Angiopoietin/Tie2 Pathway in Hepatocellular Carcinoma by Vanderborght, Bart, Lefere, Sander, Vlierberghe, Hans Van, Devisscher, Lindsey

“…Due to the usually late diagnosis and lack of effective therapies, hepatocellular carcinoma (HCC), which poses a growing global health problem, is…”
Get full text

Dataset on transcriptomic profiling of cholestatic liver injury induced by food additives and a cosmetic ingredient by Gijbels, Eva, Devisscher, Lindsey, Vinken, Mathieu

“…The provided dataset describes the differential gene expression profile of human hepatoma HepaRG cells cultured in monolayer configuration upon treatment with…”
Get full text

Synthesis, in vitro and in vivo evaluation of 3β-[18F]fluorocholic acid for the detection of drug-induced cholestasis in mice by De Lombaerde, Stef, Neyt, Sara, Kersemans, Ken, Verhoeven, Jeroen, Devisscher, Lindsey, Van Vlierberghe, Hans, Vanhove, Christian, De Vos, Filip

“…Drug-induced cholestasis is a liver disorder that might be caused by interference of drugs with the hepatobiliary bile acid transporters. It is important to…”
Get full text

Dataset on transcriptomic profiling of cholestatic liver injury in an in vitro and in vivo animal model by Gijbels, Eva, Devisscher, Lindsey, Vinken, Mathieu

“…The transcriptomic dataset (whole genome microarray Affymetrix Human U133 plus 2.0 and Affymetrix Mouse Genome 430 2.0) presented in this paper describes the…”
Get full text

Lighter serum copper isotopic composition in patients with early non-alcoholic fatty liver disease by Van Campenhout, Sanne, Hastuti, Agustina A M B, Lefere, Sander, Van Vlierberghe, Hans, Vanhaecke, Frank, Costas-Rodríguez, Marta, Devisscher, Lindsey

“…The occurrence of non-alcoholic fatty liver disease (NAFLD) is globally increasing. To challenge the current incidence of NAFLD, non-invasive markers that…”
Get full text